Human Genome Epidemiology Literature Finder
Records 1 - 5 (of 5 Records) |
Query Trace: Myasthenia Gravis and CYP3A5[original query] |
---|
Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis. European journal of neurology 2018 Aug 25 (8): 1049-e80. Chen D, Hou S, Zhao M, Sun X, Zhang H, Yang |
Monitoring of peripheral blood cluster of differentiation 4 adenosine triphosphate activity and CYP3A5 genotype to determine the pharmacokinetics, clinical effects and complications of tacrolimus in patients with autoimmune diseases. Experimental and therapeutic medicine 2018 Jan 15 (1): 532-538. Muraki Yuichi, Mizuno Shugo, Nakatani Kaname, Wakabayashi Hiroki, Ishikawa Eiji, Araki Toshimitsu, Taniguchi Akira, Isaji Shuji, Okuda Masahi |
Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study. European journal of drug metabolism and pharmacokinetics 2020 3 45 (4): 453-466. Liu Jue, Guo Yun-Peng, Jiao Zheng, Zhao Chong-Bo, Wu Hui, Li Zi-Ran, Cai Xiao-Jun, Xi Jian-Yi |
CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients. Journal of neuroimmunology 2021 Jun 355 577571. Fan Zhirong, Zheng Deqiang, Wen Xinmei, Shen Faxiu, Lei Lin, Su Shengyao, Zhang Shu, Liu Qing, Zhang Xueping, Lu Yan, Di Li, Shen Xin-Ming, Da Yuw |
Polymorphisms in drug metabolism genes predict the risk of refractory myasthenia gravis. Annals of translational medicine 2022 12 10 (21): 1155. Zhang Qing, Ge Huizhen, Gui Mengcui, Yang Mengge, Bi Zhuajin, Ma Xue, Gu Zhongya, Peng Shu, Chen Tao, Bu Bit |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: